PET/CT: nuclear medicine imaging in the future

2010 ◽  
Vol 139 (1-3) ◽  
pp. 8-11 ◽  
Author(s):  
K. A. Riklund
Keyword(s):  
Nuclear Medicine ◽  
Nuclear Medicine Imaging ◽  
Pet Ct ◽  
The Future

scholarly journals The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever…

2014 ◽  
Vol 41 (12) ◽  
pp. 2189-2193 ◽  
Author(s):  
Lisa Bodei ◽  
Mark Kidd ◽  
Vikas Prasad ◽  
Richard P. Baum ◽  
Ignat Drozdov ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Neuroendocrine Tumors ◽  
Nuclear Medicine Imaging ◽  
The Future

Comparative Study of Various Nuclear Medicine Imaging Technique - A Review

2021 ◽  
Vol 7 (3) ◽  
Author(s):  
Beena Ullala Mata B N ◽  
Anup Kumar Pal ◽  
Hrithik Sivadasan ◽  
Himanshu Mishra
Keyword(s):  
Nuclear Medicine ◽  
Multimodality Imaging ◽  
Imaging Techniques ◽  
Medical Specialty ◽  
Pharmacological Action ◽  
Individual Member ◽  
Nuclear Medicine Imaging ◽  
Pet Ct ◽  
Nuclear Medicine Instrumentation ◽  
The Impact

Nuclear Medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers (drugs linked to a radioactive isotope). The radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. The radiopharmaceuticals used in diagnostic examinations are administered in very small doses. So, in general, they have no pharmacological action, side effects or serious adverse reactions. The most serious issue with their use is the potential for diagnostic mistakes due to changes in their biodistribution. The appearance and development of new radiopharmaceuticals in both the diagnostic and therapeutic domains, as well as the impact of new multimodality imaging techniques, are all having a significant impact on nuclear medicine (SPECT-CT, PET-CT, PET-MRI, etc.). It is crucial to understand the techniques limitations, radiopharmaceutical distribution and potential physiological changes, radiological contrast contraindications and bad responses, and the possibility of both interfering. The process of generating radiopharmaceuticals is introduced and relevant interactions of radiation with matter are discussed. Diagnostic nuclear medicine instrumentation is explained, and future trends in nuclear medicine imaging technology are forecasted.

Comparative Study of Various Nuclear Medicine Imaging Technique - A Review

2021 ◽  
Vol 6 (3) ◽  
Author(s):  
Beena Ullala Mata B N ◽  
Anup Kumar Pal ◽  
Hrithik Sivadasan ◽  
Himanshu Mishra
Keyword(s):  
Nuclear Medicine ◽  
Multimodality Imaging ◽  
Imaging Techniques ◽  
Medical Specialty ◽  
Pharmacological Action ◽  
Individual Member ◽  
Nuclear Medicine Imaging ◽  
Pet Ct ◽  
Nuclear Medicine Instrumentation ◽  
The Impact

Nuclear Medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers (drugs linked to a radioactive isotope). The radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. The radiopharmaceuticals used in diagnostic examinations are administered in very small doses. So, in general, they have no pharmacological action, side effects or serious adverse reactions. The most serious issue with their use is the potential for diagnostic mistakes due to changes in their biodistribution. The appearance and development of new radiopharmaceuticals in both the diagnostic and therapeutic domains, as well as the impact of new multimodality imaging techniques, are all having a significant impact on nuclear medicine (SPECT-CT, PET-CT, PET-MRI, etc.). It is crucial to understand the techniques limitations, radiopharmaceutical distribution and potential physiological changes, radiological contrast contraindications and bad responses, and the possibility of both interfering. The process of generating radiopharmaceuticals is introduced and relevant interactions of radiation with matter are discussed. Diagnostic nuclear medicine instrumentation is explained, and future trends in nuclear medicine imaging technology are forecasted.

Nuclear Medicine Imaging of Infection/Inflammation by PET/CT and PET/MR

2019 ◽  
pp. 213-235
Author(s):  
Barbara Juarez Amorim ◽  
Benedikt Michael Schaarschmidt ◽  
Johannes Grueneisen ◽  
Shahein Tajmir ◽  
Lale Umutlu ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Nuclear Medicine Imaging ◽  
Pet Ct ◽  
Imaging Of Infection

scholarly journals Functional Imaging of Paragangliomas with an Emphasis on Von Hippel–Lindau-Associated Disease: A Mini Review

2017 ◽  
Vol 4 (3) ◽  
pp. 30-36 ◽  
Author(s):  
Ioannis Ilias ◽  
Georgios Meristoudis
Keyword(s):  
Nuclear Medicine ◽  
Functional Imaging ◽  
Somatostatin Receptors ◽  
Monoamine Transporters ◽  
Nuclear Medicine Imaging ◽  
Von Hippel Lindau ◽  
Positron Emission ◽  
Pet Ct ◽  
Vesicular Monoamine Transporters ◽  
Fdg Pet Ct

Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochromocytomas (PGLs/PHEOs) for von Hippel–Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter (hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that enter the synthesis and storage pathway of catecholamines. Nonspecific methods are not related to the synthesis, uptake, or storage of catecholamines but make use of the tumors’ high glucose metabolism or expression of somatostatin receptors. Consensuses and guidelines suggest that metastatic and sporadic PHEOs/PGLs in VHL patients (as in patients with chromaffin tumors of yet unknown genotype) should be evaluated first with 18F-dihydroxyphenylalanine (18F-DOPA) positron emission tomography/computed tomography (PET/CT). The functional imaging of second choice is 123I-metaiodobenzylguanidine (123I-MIBG) for PHEOs in VHL patients. 123I-MIBG, 68Ga-DOTATATE/DOTATOC/DOTANOC PET/CT, or 18F-fluorodeoxyglucose (18F-FDG) PET/CT can be a second choice of functional imaging for PGLs in VHL patients.

Patients with fever of unknown origin (FUO): diagnosis by nuclear medicine imaging

2001 ◽  
Vol 40 (03) ◽  
pp. 59-70 ◽  
Author(s):  
W. Becker ◽  
J. Meiler
Keyword(s):  
Nuclear Medicine ◽  
Fever Of Unknown Origin ◽  
Tumor Imaging ◽  
White Blood Cells ◽  
Unknown Origin ◽  
Final Diagnosis ◽  
Recurrent Fever ◽  
Nuclear Medicine Imaging

SummaryFever of unknown origin (FUO) in immunocompetent and non neutropenic patients is defined as recurrent fever of 38,3° C or greater, lasting 2-3 weeks or longer, and undiagnosed after 1 week of appropriate evaluation. The underlying diseases of FUO are numerous and infection accounts for only 20-40% of them. The majority of FUO-patients have autoimmunity and collagen vascular disease and neoplasm, which are responsible for about 50-60% of all cases. In this respect FOU in its classical definition is clearly separated from postoperative and neutropenic fever where inflammation and infection are more common. Although methods that use in-vitro or in-vivo labeled white blood cells (WBCs) have a high diagnostic accuracy in the detection and exclusion of granulocytic pathology, they are only of limited value in FUO-patients in establishing the final diagnosis due to the low prevalence of purulent processes in this collective. WBCs are more suited in evaluation of the focus in occult sepsis. Ga-67 citrate is the only commercially available gamma emitter which images acute, chronic, granulomatous and autoimmune inflammation and also various malignant diseases. Therefore Ga-67 citrate is currently considered to be the tracer of choice in the diagnostic work-up of FUO. The number of Ga-67-scans contributing to the final diagnosis was found to be higher outside Germany than it has been reported for labeled WBCs. F-l 8-2’-deoxy-2-fluoro-D-glucose (FDG) has been used extensively for tumor imaging with PET. Inflammatory processes accumulate the tracer by similar mechanisms. First results of FDG imaging demonstrated, that FDG may be superior to other nuclear medicine imaging modalities which may be explained by the preferable tracer kinetics of the small F-l 8-FDG molecule and by a better spatial resolution of coincidence imaging in comparison to a conventional gamma camera.

Sign in / Sign up

Export Citation Format

Share Document